MX2024008939A - Moduladores de oligonucleotidos activadores de la expresion de la utrofina. - Google Patents

Moduladores de oligonucleotidos activadores de la expresion de la utrofina.

Info

Publication number
MX2024008939A
MX2024008939A MX2024008939A MX2024008939A MX2024008939A MX 2024008939 A MX2024008939 A MX 2024008939A MX 2024008939 A MX2024008939 A MX 2024008939A MX 2024008939 A MX2024008939 A MX 2024008939A MX 2024008939 A MX2024008939 A MX 2024008939A
Authority
MX
Mexico
Prior art keywords
nucleic acid
strand
oligonucleotide
acid strand
activating
Prior art date
Application number
MX2024008939A
Other languages
English (en)
Spanish (es)
Inventor
Robert Place
Longcheng Li
Moorim Kang
Original Assignee
Ractigen Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ractigen Therapeutics filed Critical Ractigen Therapeutics
Publication of MX2024008939A publication Critical patent/MX2024008939A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C07K14/4708—Duchenne dystrophy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2024008939A 2022-01-20 2023-01-13 Moduladores de oligonucleotidos activadores de la expresion de la utrofina. MX2024008939A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022072958 2022-01-20
PCT/CN2023/072076 WO2023138502A1 (en) 2022-01-20 2023-01-13 Oligonucleotide modulators activating utrophin expression

Publications (1)

Publication Number Publication Date
MX2024008939A true MX2024008939A (es) 2024-07-29

Family

ID=87347803

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024008939A MX2024008939A (es) 2022-01-20 2023-01-13 Moduladores de oligonucleotidos activadores de la expresion de la utrofina.

Country Status (10)

Country Link
US (1) US20250101421A1 (cg-RX-API-DMAC7.html)
EP (1) EP4466359A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025504474A (cg-RX-API-DMAC7.html)
KR (1) KR20250005567A (cg-RX-API-DMAC7.html)
CN (1) CN118829728A (cg-RX-API-DMAC7.html)
AU (1) AU2023209973A1 (cg-RX-API-DMAC7.html)
CA (1) CA3249545A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024008939A (cg-RX-API-DMAC7.html)
TW (1) TW202338088A (cg-RX-API-DMAC7.html)
WO (1) WO2023138502A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025201529A1 (en) * 2024-03-29 2025-10-02 Ractigen Therapeutics Compounds for synthesizing modified small activating rna molecules, modified small activating rna molecules and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916532B2 (en) * 2008-04-28 2014-12-23 The Trustees Of The University Of Pennsylvania Methods for enhancing utrophin production via inhibition of microRNA
EP2427554B1 (en) * 2009-05-08 2016-11-16 CuRNA, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
CN104540946A (zh) * 2012-05-16 2015-04-22 Rana医疗有限公司 用于调节utrn表达的组合物和方法
US20170044540A1 (en) * 2014-04-22 2017-02-16 Mina Therapeutics Limited Sarna compositions and methods of use
WO2019183005A1 (en) * 2018-03-19 2019-09-26 The Trustees Of The University Of Pennsylvania 2'f-ana-let7 mediated utrophin upregulation for dmd therapy
WO2021230385A1 (en) * 2020-05-15 2021-11-18 Astellas Pharma Inc. Method for treating muscular dystrophy by targeting utrophin gene

Also Published As

Publication number Publication date
CA3249545A1 (en) 2023-07-27
US20250101421A1 (en) 2025-03-27
KR20250005567A (ko) 2025-01-09
TW202338088A (zh) 2023-10-01
CN118829728A (zh) 2024-10-22
EP4466359A4 (en) 2026-07-01
AU2023209973A1 (en) 2024-09-05
EP4466359A1 (en) 2024-11-27
JP2025504474A (ja) 2025-02-12
WO2023138502A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
Furdon et al. RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds
JP2020072724A5 (cg-RX-API-DMAC7.html)
FI4220360T3 (fi) Oligonukleotideja paternaalisen ube3a:n ilmentämiseksi
JP2015518713A5 (cg-RX-API-DMAC7.html)
KR930701466A (ko) 안티센스 올리고뉴클레오티드에 의한 a형 인플루엔자 바이러스, 안 아아보 스트레인(ann arbor strain)h2n2의 억제
JP2015518710A5 (cg-RX-API-DMAC7.html)
BRPI0811170B8 (pt) oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila
EP4455285A3 (en) Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
JP2015519057A5 (cg-RX-API-DMAC7.html)
KR960701077A (ko) 올리고누클레오티드 알킬포스포네이트 및 알킬포스포노티오에이트(oligonucleotide alkylphosphonates and alkylphosphonothioates)
JP2015523853A5 (cg-RX-API-DMAC7.html)
JP2009532392A5 (cg-RX-API-DMAC7.html)
JP2016522674A5 (cg-RX-API-DMAC7.html)
RU2011127211A (ru) Лечение сиртуин 1 (sirt1-связанных заболеваний путем ингибирования натурального антисмыслового транскрипта
PH12021551544A1 (en) Oligomeric nucleic acid molecule and application thereof
JP2015518711A5 (cg-RX-API-DMAC7.html)
JP2012525852A5 (cg-RX-API-DMAC7.html)
Yagi et al. Chimeric RNA and 2′-O, 4′-C-ethylene-bridged nucleic acids have stronger activity than phosphorothioate oligodeoxynucleotides in induction of exon 19 skipping in dystrophin mRNA
US9970004B2 (en) Nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell, induction method of RNA interferencde in eukaryotic host and use of the nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide CAG repeats
Hatta et al. Specific inhibition of influenza virus RNA polymerase and nucleoprotein genes expression by liposomally endocapsulated antisense phosphorothioate oligonucleotides: penetration and localization of oligonucleotides in clone 76 cells
Osako et al. Increase in nuclease resistance and incorporation of NF‐κB decoy oligodeoxynucleotides by modification of the 3′‐terminus
US20220135972A1 (en) Optimal ps modification pattern for heteronucleic acids
AU2014250708B2 (en) Oligonucleotides for modulating target RNA activity
Hatta et al. Inhibition of influenza virus RNA polymerase and nucleoprotein genes expression by unmodified, phosphorothioated, and liposomally encapsulated oligonucleotides
Peyrottes et al. Dramatic effect of the anomeric configuration on the thermal stability of duplex formed between novel dodecathymidine phosphoramidate (PNH2) and complementary DNA and RNA strands